BioMarin Pharmaceuticals
BMRN
About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Employees: 3,040
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
30% more repeat investments, than reductions
Existing positions increased: 239 | Existing positions reduced: 184
17% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 7 (+1) [Q2]
11% more call options, than puts
Call options by funds: $81.1M | Put options by funds: $73M
5% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 81
0.01% more ownership
Funds ownership: 96.07% [Q1] → 96.08% (+0.01%) [Q2]
1% less funds holding
Funds holding: 578 [Q1] → 574 (-4) [Q2]
21% less capital invested
Capital invested by funds: $12.9B [Q1] → $10.1B (-$2.73B) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
HC Wainwright & Co.
Mitchell S. Kapoor
|
$60
|
Neutral
Initiated
|
8 Sep 2025 |
|
Guggenheim
Debjit Chattopadhyay
|
$106
|
Buy
Maintained
|
6 Aug 2025 |
|
UBS
Eliana Merle
|
$114
|
Buy
Maintained
|
5 Aug 2025 |
|
Morgan Stanley
Matthew Harrison
|
$96
|
Overweight
Maintained
|
22 Jul 2025 |
|
JP Morgan
Jessica Fye
|
$113
|
Overweight
Maintained
|
14 Jul 2025 |
Financial journalist opinion
Based on 11 articles about BMRN published over the past 30 days
